drugset

drugset / Trial / NCT05792527

L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis

NCT05792527 ↗

Phase 3 Unknown 46 enrolled Tanta University

RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims at evaluating the possible efficacy and safety of L-carnitine in rheumatoid arthritis via targeting Jak/STAT pathway and TGF-β1

Timeline

Start: 2023-03-05
Primary completion: 2025-03-05
Completion: 2026-03-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	L-carnitine	Other / unclassified	500 mg	—

Indications